Johannes Jacob Pieter Kastelein, Chief Scientific Officer at NewAmsterdam Pharma Co N.V. (NAMS), sold 150,000 shares at $24.29 ($3.7M) on 2025-08-21, disclosed to the SEC on 2025-08-25.
Open-market sale of $3.7M NAMS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.29 | 50,000 | $1.2M | 32.6% |
| 2 | $25.08 | 42,342 | $1.1M | 28.5% |
| 3 | $25.08 | 42,342 | $1.1M | 28.5% |
| 4 | $25.49 | 7,658 | $195K | 5.2% |
| 5 | $25.49 | 7,658 | $195K | 5.2% |
| Total | $24.86 avg | 150,000 |
| $3.7M |
| 100% |
| Filing → |
| NAMS | SELL | 2026-02-24 | $1.6M | — | Filing → |
| NAMS | SELL | 2026-01-07 | $200K | — | Filing → |
| NAMS | SELL | 2024-03-27 | $4.1M | — | Filing → |